75 related articles for article (PubMed ID: 3723137)
1. A randomized trial of low doses of alpha interferon in patients with breast cancer.
Laszlo J; Hood L; Cox E; Goodwin B
J Biol Response Mod; 1986 Jun; 5(3):206-10. PubMed ID: 3723137
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
Sarna GP; Figlin RA
Cancer Treat Rep; 1985 May; 69(5):547-9. PubMed ID: 4005877
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.
Kirkwood JM; Harris JE; Vera R; Sandler S; Fischer DS; Khandekar J; Ernstoff MS; Gordon L; Lutes R; Bonomi P
Cancer Res; 1985 Feb; 45(2):863-71. PubMed ID: 3881175
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
5. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
6. Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients.
Silver HK; Connors JM; Karim KA; Kong S; Spinelli JJ; de Jong G; McLean DM; Salinas FA
J Biol Response Mod; 1983; 2(5):428-40. PubMed ID: 6644347
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
9. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
10. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.
Krown SE; Mintzer D; Cunningham-Rundles S; Niedzwiecki D; Krim M; Einzig AI; Gabrilove JL; Shurgot B; Gessula J
Cancer Treat Rep; 1987 Jan; 71(1):39-45. PubMed ID: 3791267
[TBL] [Abstract][Full Text] [Related]
11. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
[TBL] [Abstract][Full Text] [Related]
12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
13. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
15. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment.
Eggermont AM; Weimar W; Marquet RL; Laméris JD; Jeekel J
Cancer Treat Rep; 1985 Feb; 69(2):185-7. PubMed ID: 3882227
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Laszlo J
J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma.
Goldberg RM; Ayoob M; Silgals R; Ahlgren JD; Neefe JR
Cancer Treat Rep; 1985; 69(7-8):813-6. PubMed ID: 4016791
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.
Sarosy GA; Brown TD; Von Hoff DD; Spiegel RJ; Golando JP; Beougher KL; Kuhn JG; Kisner DL
Cancer Res; 1986 Oct; 46(10):5368-71. PubMed ID: 3756887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
